Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon 97239, USA.
J Clin Invest. 2013 Jun;123(6):2337-43. doi: 10.1172/JCI67225. Epub 2013 Jun 3.
Hepcidin is a key hormone that is involved in the control of iron homeostasis in the body. Physiologically, hepcidin is controlled by iron stores, inflammation, hypoxia, and erythropoiesis. The regulation of hepcidin expression by iron is a complex process that requires the coordination of multiple proteins, including hemojuvelin, bone morphogenetic protein 6 (BMP6), hereditary hemochromatosis protein, transferrin receptor 2, matriptase-2, neogenin, BMP receptors, and transferrin. Misregulation of hepcidin is found in many disease states, such as the anemia of chronic disease, iron refractory iron deficiency anemia, cancer, hereditary hemochromatosis, and ineffective erythropoiesis, such as β-thalassemia. Thus, the regulation of hepcidin is the subject of interest for the amelioration of the detrimental effects of either iron deficiency or overload.
亚铁调素是一种关键的激素,参与体内铁稳态的控制。在生理上,亚铁调素受铁储存、炎症、缺氧和红细胞生成的控制。铁对亚铁调素表达的调节是一个复杂的过程,需要多种蛋白质的协调,包括亚铁调素、骨形成蛋白 6(BMP6)、遗传性血色素沉着症蛋白、转铁蛋白受体 2、组织蛋白酶-2、新生蛋白、BMP 受体和转铁蛋白。亚铁调素的失调存在于许多疾病状态中,如慢性病贫血、铁难治性缺铁性贫血、癌症、遗传性血色素沉着症和无效性红细胞生成,如β-地中海贫血。因此,亚铁调素的调节是改善铁缺乏或过载的不利影响的研究重点。